The EBMT and the EHA announce a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.

The Gemeinsame Bundesausschuss (G-BA) published its directions on the treatment of German patients with CAR T-cell therapies.

The EBMT announced the results of the phase III RACE trial during EBMTs virtual 46^th Annual Meeting.

The EBMT announces a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR T) therapy.

Over 1,200 European researchers, clinicians, nurses, patients, regulators, and industry are gathering in Sitges for the 2 nd European CAR T Cell Meeting, organized by the EBMT and EHA.

CAR T Cell Therapy; updates on efficacy and targets in 2nd European Meeting organized by EBMT and EHA in Sitges (Barcelona), Spain, on January 30 - February 1, 2020.

The EBMT registry has been qualified by EMA as a suitable platform for the collection of data for post-authorisation safety surveillance and efficacy studies.